Clinical trial recruitment specialist Trialbee has secured a majority investment from Varsity Healthcare Partners, a strategic move aimed at enhancing the company’s technology and global capabilities. This investment reflects the rising demand for efficient trial enrollment solutions as biopharmaceutical companies face increasing complexities in attracting participants for clinical studies.
Although financial terms of the investment were not disclosed, this deal grants Varsity Healthcare Partners a controlling stake in Trialbee. Existing investors MTIP and Industrifonden will continue to hold minority stakes. The additional capital will expedite the expansion of Trialbee’s Honey Platform, allowing for wider enterprise-level recruitment offerings and improved international delivery capabilities within its extensive partner ecosystem.
Trialbee operates in a critical area of clinical research, focusing on patient identification, feasibility analysis, and site engagement. As sponsors struggle with delays that can significantly affect drug development timelines and costs, the company aims to streamline the recruitment process. Matt Walz, Chief Executive Officer of Trialbee, emphasized that the partnership with Varsity will enable the company to enhance predictability for sponsors, contract research organizations, and trial sites worldwide. His vision is to precisely connect patients with research sites, ultimately ensuring that studies meet their enrollment targets on time and within budget.
Over the past year, Trialbee has broadened its global reach, collaborating with over 6,000 research sites across 50 countries and supporting clinical trials conducted in 66 languages. The company reported that it screened more than 1.5 million patients in 2025, aided by the development of new sponsor-specific registries and strengthened data partnerships that improve patient-aligned feasibility and enrollment projections.
Varsity Healthcare Partners specializes in investing in healthcare services and technology businesses that facilitate large-scale clinical operations. Partner Navid Gharavi noted that Trialbee aligns with their strategy of supporting established platforms that have the potential for operational growth. The firm was particularly impressed by Trialbee’s commitment to customer outcomes and its innovative use of data and analytics to address ongoing challenges in clinical research.
The timing of this investment comes as biopharmaceutical sponsors face intense scrutiny regarding trial timelines and enrollment efficiency. With protocols becoming more specialized and eligibility criteria tightening, recruitment failures continue to be a leading cause of delays and cost overruns in the industry. Despite this new chapter, Trialbee’s leadership and mission will remain consistent as it embarks on its next growth phase.
The financial advisory firm Stout provided guidance to Trialbee during this transaction. With new capital and a majority owner, Trialbee is well-positioned to serve as an infrastructure partner for sponsors seeking to modernize the identification, engagement, and enrollment of patients in clinical trials on a global scale.
